search
Back to results

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection (LIZ-BONE)

Primary Purpose

Hip Prosthetic Joint Infection

Status
Unknown status
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
VANCOMYCIN
CEFTRIAXONE
CLINDAMYCIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)
FLUOROQUINOLONE
LINEZOLID
RIFAMPIN
Sponsored by
University Hospital, Tours
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Prosthetic Joint Infection focused on measuring Antibiotic, linezolid, linezolid/rifampin

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Men or women ≥ 18 to ≤ 80 years of age, weight ≥ 40 kg, BMI < 35, who have received a diagnosis of chronic PJI (lasting more than 4 weeks but less than 24 months) requiring a one-stage surgical procedure and presenting at least ONE of the following clinical signs and symptoms:

    1. Joint pain
    2. Effusion
    3. Erythema and sensation of heat at the implant site
    4. Limited range of motion in the affected joint
  2. Intraoperative microbiological specimens: during the surgical resection, 5 separate surgical specimens (at least 3) must be sent for culture and susceptibility testing. These specimens must be taken from different locations such as: Hip capsule, femoral membrane, acetabular membrane, synovium, and synovial fluid with separate instruments. A minimum of 2 surgical specimens must be positive. If a preoperative puncture revealed the presence of an acceptable (Gram+) pathogen, it is acceptable if only one pathogen similar to the previously revealed one is identified during the surgical procedure.
  3. Documented presence of Gram-positive bacteria as sole pathogen responsible for the infection.

    Note: This criterion must be verified after obtaining the results of the susceptibility test performed on the specimens taken during the surgical procedure. The verification will occur between Day 2 and Day 7 of the study.

  4. All patients must undergo 1-stage revision surgery.
  5. IRB or IEC approved informed consent form signed and dated. Informed consent will be obtained from each patient before participation in this research study. If any patient is unable to give consent, it may be obtained from the patient's next of kin or legal representative in accordance with current laws and regulations.
  6. Willing and able to comply with scheduled visits, up to 6 weeks of treatment with the study antibiotics, laboratory tests, and other study procedures.
  7. Patient entitled to Health System benefits or other such benefits

Exclusion Criteria:

  1. Concerning women of childbearing age:

    1. intake of oral contraceptives (estroprogestins and progestins)
    2. unability to use adequate mechanical contraceptive precautions
    3. a positive pregnancy test result within 72 hours prior to randomization
    4. pregnant, or are currently breastfeeding and unwilling to discontinue breastfeeding during therapy
  2. Patients with a prosthetic joint infection caused by: Gram-negative, mixed Gram-negative and Gram-positive, fungal, or mycobacterial microorganisms. If a previous radiologically guided puncture has revealed the presence of a Gram-negative microorganism, the patient must not be enrolled in this study.
  3. Platelet count less than 100 ×103/mm3 at the time of the examination performed during the screening period.
  4. Hemoglobin < 9 g/dL at the time of the examination performed during the screening period.
  5. Infection affecting several joints.
  6. Rheumatological disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.)
  7. Previously diagnosed immune function disease(s) (e.g., AIDS), neutropenia (neutrophils < 1000/mm3).
  8. Alcoholism or substance abuse sufficient, in the investigator's judgment, to prevent treatment adherence to the study drug and/or follow-up.
  9. Patients currently in peritoneal dialysis or receiving another treatment for renal failure (e.g., hemofiltration, CVVH).
  10. Liver failure with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin levels upper or egal to 5 times the upper limit of normal.
  11. Patients with other concurrent serious infections such as: endocarditis, meningitis, or central nervous system (CNS) infections, decubitus and ischemic ulcers with underlying osteomyelitis, necrotizing fasciitis, gas gangrene. If suspected, these diagnoses must be ruled out prior to enrollment in the study.
  12. Previous randomization in this protocol.
  13. Not expected or not likely to survive for the entire duration of the treatment period and TOC (12 months after the end of treatment).
  14. Hypersensitivity to the study drugs or their excipients.
  15. Identification of a pathogen resistant to the investigational drugs.
  16. Patients treated with a protease inhibitor(e.g. indinavir, ritonavir), or with delavirdine, or with nevirapine.
  17. Patients treated or having been treated within two weeks prior surgery with an MAOI (A or B), an antiserotonergic drug, a tricyclic antidepressant, an agonist of 5HT1-receptor(triptan), a direct or indirect sympathomimetic drug (including adrenergic bronchodilator, pseudoephedrin, phenylpropanolamin), a vasopressor (adrenalin, noradrenalin), dopaminergic drug, pethidin or buspirone,
  18. Patients with a degenerative neurological disease (Parkinson's disease, multiple sclerosis, Alzheimer's disease, etc.).
  19. Patient presenting an uncontrolled hypertension, a pheochromocytoma, a carcinoid syndrome, a hyperthyroidism, a bipolar depression, a dysthymic schizophrenia, an acute confusional state, pophyria or a history of retrobulbar optic neuritis.
  20. Patient who is participating or has participated in a clinical trial in the month prior to the study screening visit.

Sites / Locations

  • CHRU de ToursRecruiting
  • CHU de NantesRecruiting
  • CHU de Poitiers
  • Centre de Chirurgie Orthopédique et de la MainRecruiting
  • CH de Tourcoing
  • Azienda Opedaliera Universitaria San Maria della MisericordiaRecruiting
  • Hospital Clinic of BarcelonaRecruiting
  • Hospital General Universitario Gregorio Maranon
  • Hospital Son Llatzer

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Treatment A

Treatment B

Treatment C

Arm Description

IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.

IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.

IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.

Outcomes

Primary Outcome Measures

Clinical cure rate
Clinical cure rate in the modified intent-to-treat (mITT)population during the hospital visit. Patients will be declared cured if clinical signs of infection are normalized.

Secondary Outcome Measures

Cure rate
Cure rate ine the modified intent-to-treat population during the hospital visit. Patients will be cdeclared cured if radiological and laboratory signs of infection are normalized.
Cure rate
Patients will be declared cured if clinical, radiological, and laboratory signs of infection normalized.

Full Information

First Posted
December 20, 2012
Last Updated
May 27, 2014
Sponsor
University Hospital, Tours
Collaborators
Pfizer, International Clinical Trials Association
search

1. Study Identification

Unique Protocol Identification Number
NCT01757236
Brief Title
Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
Acronym
LIZ-BONE
Official Title
Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Unknown status
Study Start Date
October 2012 (undefined)
Primary Completion Date
April 2016 (Anticipated)
Study Completion Date
April 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Tours
Collaborators
Pfizer, International Clinical Trials Association

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy of oral linezolid-rifampin combination therapy (over 4 or 6 weeks) versus the standard of care in the treatment of Gram-positive prosthetic hip joint infection with a one-stage surgical treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Prosthetic Joint Infection
Keywords
Antibiotic, linezolid, linezolid/rifampin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment A
Arm Type
Active Comparator
Arm Description
IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.
Arm Title
Treatment B
Arm Type
Experimental
Arm Description
IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.
Arm Title
Treatment C
Arm Type
Experimental
Arm Description
IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
Intervention Type
Drug
Intervention Name(s)
VANCOMYCIN
Other Intervention Name(s)
VANCOCIN
Intervention Type
Drug
Intervention Name(s)
CEFTRIAXONE
Other Intervention Name(s)
ROCEPHIN
Intervention Type
Drug
Intervention Name(s)
CLINDAMYCIN
Other Intervention Name(s)
DALACIN
Intervention Type
Drug
Intervention Name(s)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)
Other Intervention Name(s)
BACTRIM
Intervention Type
Drug
Intervention Name(s)
FLUOROQUINOLONE
Other Intervention Name(s)
OFLOCIN
Intervention Type
Drug
Intervention Name(s)
LINEZOLID
Other Intervention Name(s)
ZYVOXID
Intervention Type
Drug
Intervention Name(s)
RIFAMPIN
Other Intervention Name(s)
RIFADIN
Primary Outcome Measure Information:
Title
Clinical cure rate
Description
Clinical cure rate in the modified intent-to-treat (mITT)population during the hospital visit. Patients will be declared cured if clinical signs of infection are normalized.
Time Frame
12 months after the end of treatment
Secondary Outcome Measure Information:
Title
Cure rate
Description
Cure rate ine the modified intent-to-treat population during the hospital visit. Patients will be cdeclared cured if radiological and laboratory signs of infection are normalized.
Time Frame
12 months after the end of treatment
Title
Cure rate
Description
Patients will be declared cured if clinical, radiological, and laboratory signs of infection normalized.
Time Frame
6 and 24 months after the end of treatment for the modified intent-to-treat population and at 12 months for the per protocol population.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men or women ≥ 18 to ≤ 80 years of age, weight ≥ 40 kg, BMI < 35, who have received a diagnosis of chronic PJI (lasting more than 4 weeks but less than 24 months) requiring a one-stage surgical procedure and presenting at least ONE of the following clinical signs and symptoms: Joint pain Effusion Erythema and sensation of heat at the implant site Limited range of motion in the affected joint Intraoperative microbiological specimens: during the surgical resection, 5 separate surgical specimens (at least 3) must be sent for culture and susceptibility testing. These specimens must be taken from different locations such as: Hip capsule, femoral membrane, acetabular membrane, synovium, and synovial fluid with separate instruments. A minimum of 2 surgical specimens must be positive. If a preoperative puncture revealed the presence of an acceptable (Gram+) pathogen, it is acceptable if only one pathogen similar to the previously revealed one is identified during the surgical procedure. Documented presence of Gram-positive bacteria as sole pathogen responsible for the infection. Note: This criterion must be verified after obtaining the results of the susceptibility test performed on the specimens taken during the surgical procedure. The verification will occur between Day 2 and Day 7 of the study. All patients must undergo 1-stage revision surgery. IRB or IEC approved informed consent form signed and dated. Informed consent will be obtained from each patient before participation in this research study. If any patient is unable to give consent, it may be obtained from the patient's next of kin or legal representative in accordance with current laws and regulations. Willing and able to comply with scheduled visits, up to 6 weeks of treatment with the study antibiotics, laboratory tests, and other study procedures. Patient entitled to Health System benefits or other such benefits Exclusion Criteria: Concerning women of childbearing age: intake of oral contraceptives (estroprogestins and progestins) unability to use adequate mechanical contraceptive precautions a positive pregnancy test result within 72 hours prior to randomization pregnant, or are currently breastfeeding and unwilling to discontinue breastfeeding during therapy Patients with a prosthetic joint infection caused by: Gram-negative, mixed Gram-negative and Gram-positive, fungal, or mycobacterial microorganisms. If a previous radiologically guided puncture has revealed the presence of a Gram-negative microorganism, the patient must not be enrolled in this study. Platelet count less than 100 ×103/mm3 at the time of the examination performed during the screening period. Hemoglobin < 9 g/dL at the time of the examination performed during the screening period. Infection affecting several joints. Rheumatological disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.) Previously diagnosed immune function disease(s) (e.g., AIDS), neutropenia (neutrophils < 1000/mm3). Alcoholism or substance abuse sufficient, in the investigator's judgment, to prevent treatment adherence to the study drug and/or follow-up. Patients currently in peritoneal dialysis or receiving another treatment for renal failure (e.g., hemofiltration, CVVH). Liver failure with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin levels upper or egal to 5 times the upper limit of normal. Patients with other concurrent serious infections such as: endocarditis, meningitis, or central nervous system (CNS) infections, decubitus and ischemic ulcers with underlying osteomyelitis, necrotizing fasciitis, gas gangrene. If suspected, these diagnoses must be ruled out prior to enrollment in the study. Previous randomization in this protocol. Not expected or not likely to survive for the entire duration of the treatment period and TOC (12 months after the end of treatment). Hypersensitivity to the study drugs or their excipients. Identification of a pathogen resistant to the investigational drugs. Patients treated with a protease inhibitor(e.g. indinavir, ritonavir), or with delavirdine, or with nevirapine. Patients treated or having been treated within two weeks prior surgery with an MAOI (A or B), an antiserotonergic drug, a tricyclic antidepressant, an agonist of 5HT1-receptor(triptan), a direct or indirect sympathomimetic drug (including adrenergic bronchodilator, pseudoephedrin, phenylpropanolamin), a vasopressor (adrenalin, noradrenalin), dopaminergic drug, pethidin or buspirone, Patients with a degenerative neurological disease (Parkinson's disease, multiple sclerosis, Alzheimer's disease, etc.). Patient presenting an uncontrolled hypertension, a pheochromocytoma, a carcinoid syndrome, a hyperthyroidism, a bipolar depression, a dysthymic schizophrenia, an acute confusional state, pophyria or a history of retrobulbar optic neuritis. Patient who is participating or has participated in a clinical trial in the month prior to the study screening visit.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Louis BERNARD
Phone
+ 33 (0) 2 47 47 97 74
Ext
79774
Email
l.bernard@chu-tours.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Louis BERNARD
Organizational Affiliation
CHRU de Tours FRANCE
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David BOUTOILLE
Organizational Affiliation
CHU de Nantes FRANCE
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gwenael LE MOAL
Organizational Affiliation
CHU de Poitiers FRANCE
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Matteo BASSETTI
Organizational Affiliation
Azienda Opedaliera Universitaria San Maria della Misericordia ITALY
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Silvano ESPOSITO
Organizational Affiliation
Facolta di Medicina e Chirugia ITALY
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeannot GAUDIAS
Organizational Affiliation
Centre de Chirurgie Orthopédique et de la Main FRANCE
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alex SORIANO
Organizational Affiliation
Hospital Clinic of Barcelona SPAIN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bartolome LLADO FERRER
Organizational Affiliation
Hospital Son Llatzer Palma Balears SPAIN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mar SANCHEZ SOMOLINOS
Organizational Affiliation
HGU Gregorio Maranon Madrid SPAIN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eric SENNEVILLE
Organizational Affiliation
CH de Tourcoing FRANCE
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHRU de Tours
City
Tours
State/Province
Indre et Loire
ZIP/Postal Code
37044
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louis BERNARD
Phone
+33 (0) 2 47 47 97 74
Email
l.bernard@chu-tours.fr
First Name & Middle Initial & Last Name & Degree
Louis BERNARD
Facility Name
CHU de Nantes
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David BOUTOILLE
First Name & Middle Initial & Last Name & Degree
David BOUTOILLE
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gwenaël LE MOAL
First Name & Middle Initial & Last Name & Degree
Gwenaël LE MOAL
Facility Name
Centre de Chirurgie Orthopédique et de la Main
City
Strasbourg
ZIP/Postal Code
67400
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeannot GAUDIAS
Email
Jeannot.GAUDIAS@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Jeannot GAUDIAS
Facility Name
CH de Tourcoing
City
Tourcoing
ZIP/Postal Code
59208
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric SENNEVILLE
Email
esenneville@ch-tourcoing.fr
First Name & Middle Initial & Last Name & Degree
Eric SENNEVILLE
Facility Name
Azienda Opedaliera Universitaria San Maria della Misericordia
City
Udine
ZIP/Postal Code
33100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matteo BASSETTI
Email
mattba@tin.it
First Name & Middle Initial & Last Name & Degree
Matteo BASSETTI
Facility Name
Hospital Clinic of Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alex SORIANO
Email
ASORIANO@clinic.ub.es
First Name & Middle Initial & Last Name & Degree
Alex SORIANO
Facility Name
Hospital General Universitario Gregorio Maranon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mar SANCHEZ SOMOLINOS
First Name & Middle Initial & Last Name & Degree
Mar SANCHEZ SOMOLINOS
Facility Name
Hospital Son Llatzer
City
Palma de Mallorca
ZIP/Postal Code
07198
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bartolome LLADO FERRER
First Name & Middle Initial & Last Name & Degree
Bartolome LLADO FERRER

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection

We'll reach out to this number within 24 hrs